News|Articles|February 23, 2026

FDA Grants Fast Track to ART6043 for BRCA-Mutated Advanced Breast Cancer

Fact checked by: Alex Biese

Listen

0:00 / 0:00

Key Takeaways

FDA fast track covers ART6043 plus olaparib in PARP inhibitor–naïve gBRCAm, HER2-negative locally advanced/metastatic breast cancer, enabling earlier FDA engagement and potential priority review/accelerated approval pathways.
Polθ inhibition targets MMEJ, exploiting tumor reliance on error-prone DNA repair and aiming to extend PARP-based efficacy by disrupting compensatory repair mechanisms driving resistance.
ESMO 2025 signals from an ongoing phase 1/2a program showed expected PK/PD and encouraging activity in DDR-mutant solid tumors, supporting enhanced anti-tumor effects in gBRCAm contexts.
Safety observations suggested favorable tolerability, consistent with Polθ’s cancer-selective expression profile, supporting continued combination development alongside DNA-damaging therapeutic modalities.

The FDA granted fast track status to ART6043 plus Lynparza for patients with gBRCA-mutated HER2-negative breast cancer to accelerate drug development.

The U.S. Food and Drug Administration (FDA) has granted fast track designation to the pharmaceutical company Artios for its DNA polymerase theta (Polθ) inhibitor, ART6043, to be used in combination with the PARP inhibitor Lynparza (olaparib). This designation applies to the treatment of adult patients with germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer who have not previously received treatment with a PARP inhibitor.

The FDA's fast track program is intended to facilitate the development and speed up the review of investigational medicines that show potential to address unmet medical needs for serious or life-threatening conditions. Breast cancer is the second leading cause of cancer death among women in the United States, and patients with a BRCA mutation often develop resistance to treatment when using a PARP inhibitor alone. By inhibiting Polθ, a DNA repair enzyme, ART6043 is designed to improve clinical outcomes and survival rates by removing the ability of a cancer cell to repair itself.

Main data that support the findings

The designation was granted based on data from an ongoing study evaluating ART6043 in combination with Lynparza. In findings presented at the European Society for Medical Oncology (ESMO) Congress 2025, the drug combination demonstrated promising clinical signals in patients with advanced solid tumors. ART6043 is an oral small-molecule inhibitor that targets the polymerase domain of Polθ, an enzyme that is expressed in cancer cells but is virtually absent in most healthy tissues.

By inhibiting this enzyme, the treatment targets microhomology-mediated end joining (MMEJ). This process exploits the dependence of a tumor on error-prone DNA repair. The data presented at the congress showed expected pharmacokinetic and pharmacodynamic activity, which describes how the drug moves through and affects the body. Researchers noted that the combination showed encouraging clinical activity in the relevant genetic background, supporting the potential for ART6043 to enhance anti-tumor activity by removing a cancer cell's reliance on Polθ as a repair mechanism. This approach aims to overcome key mechanisms of resistance that often occur in patients with BRCA mutations, who may face aggressive disease and a high risk of recurrence due to BRCA reversions.

Trial details

The clinical evidence stems from the ongoing, first-in-human, phase 1/2a study. This trial evaluates ART6043 in combination with Lynparza specifically in patients with advanced solid tumors that harbor mutations in DNA Damage Response (DDR) pathways, including gBRCAm HER2-negative breast cancer. The study is designed to evaluate the drug in molecularly defined settings, including cases involving BRCA variants and resistance to PARP inhibitors.

The fast track designation will allow Artios to interact more frequently and earlier with the FDA to discuss the development path for ART6043. Under this program, the drug candidate is eligible for priority review and accelerated approval if it meets the relevant clinical criteria. The company's strategy involves evaluating how ART6043 can enhance target engagement and anti-tumor activity in well-defined patient populations who currently have limited treatment options.

Safety

In data presented at the ESMO Congress 2025, ART6043 demonstrated an attractive tolerability profile. The Phase 1/2a study has shown a favorable pharmacology profile, indicating that the drug is functioning as intended within the body. Because Polθ is preferentially expressed in cancer cells and is virtually absent in healthy tissues, the treatment is designed to maintain tolerability while increasing the effectiveness of the therapy. The ongoing trial continues to monitor the safety of ART6043 in combination with Lynparza to ensure it can be used effectively alongside other DNA-damaging modalities. This focus on tolerability is a key component of the clinical profile recognized by the FDA through the granting of the fast track designation.

Reference:

“Artios Receives U.S. FDA Fast Track Designation for DNA Polymerase Theta (Polθ) Inhibitor ART6043 for Treatment of gBRCA-mutated HER2-Negative Breast Cancer,” news release; https://www.artios.com/press-release/artios-receives-u-s-fda-fast-track-designation-for-dna-polymerase-theta-pol%ce%b8-inhibitor-art6043-for-treatment-of-gbrca-mutated-her2-negative-breast-cancer/

Editor's note: This article is for informational purposes only and is not a substitute for professional medical advice, as your own experience will be unique. Use this article to guide discussions with your oncologist. Content was generated with AI, reviewed by a human editor, but not independently verified by a medical professional.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.